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Purpose/Objective: Hepatocellular carcinoma (HCC) is multi-
centric disease, and most of the patients suffer from 
recurrence. In general, tolerance dose of the liver is not very 
high, therefore, stereotactic radiotherapy for small tumor (<= 
5 cm) is popular strategy of photon radiotherapy. In contrast, 
we have conducted definitive proton beam therapy (PBT) for 
many patients even with large HCC. And some of the patients 
received PBT repeatedly because of the recurrence. The 
purpose of this study is to analyze the course of repeated PBT 
for liver HCC, and evaluated its safety and efficacy. 
Materials and Methods: Patients who received multiple 
course of definitive PBT (>= 50 GyE) for liver HCC from 2002 
to 2012 were retrospectively analyzed. Proton beams were 
delivered with respiratory gating. Eighty-eight patients 
received PBT for 2-4 courses of PBT. The patients group 
included 70 male and 18 female, and the median age of the 
patients was 69 years old (range: 46 – 86). Eleven and 63 
patients were infected by hepatitis-B and hepatitis-C virus, 
respectively, and 14 patients were not infected with 
hepatitis virus. 
Results: The number of treatment course was 2, 3, 4 for 66, 
18, 4 patients, respectively. The median planned total doses 
was 70.0 GyE for all tumors of all patients, and the median 
dose for 1st, 2nd, 3rd and 4th treatment was 70.0, 71.3, 71.3, 
and 69.3 GyE, respectively. The median CTV was 28.5 cc (2.8 
- 936.2 cc) for of all treatment of all the patients, and 34, 
25, 14, 36 cc for the 1st, 2nd, 3rd and 4th treatment. Fifty-nine 
patients received PBT for completely different tumors 
outside of the previous treatment fields, but 22 and 7 
patients received PBT for the recurrent tumor within the 
previous fields and for the marginal recurrent tumor. The 
median follow up period from the start of the first PBT was 
45 months, and the median overall survival from the first PBT 
was 61 months for all patients (95% CI: 52 - 70 months). 
Severe acute and chronic toxicity was not observed. Eight 
patients were dead of hepatic failure, but all of which were 
induced by disease progression. Serious radiation induced 
liver disease was not observed. 
Conclusions: Definitive repeated PBT for liver HCC is safe 
and effective. 
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Purpose/Objective: The spleen often receives a high dose in 
chemoradiotherapy (CRT) for gastric cancer, due to its 
anatomical location and the fact that its hilar region is part 
of the CTV. Yet, the spleen is not considered as organ at risk, 
because it is largely unknown whether and to what extent 
the splenic function is affected by radiation (RT). However, 
histological changes of the spleen after irradiation, such as a 
decreased organ weight and white pulp depletion, have been 
described. Furthermore, following surgical splenectomy, 
patients are at an increased risk for fatal thromboembolic 
events and infections. The objective of this retrospective 
study was to investigate radiation-induced changes of the 
spleen after postoperative CRT for gastric cancer. 
Materials and Methods: We included gastric cancer patients 
who received postoperative CRT, consisting of 45 Gy RT with 
concurrent capecitabine and cisplatin, in our institute 
between 2006-2011. The spleen was manually delineated on 
the RT-planning CT-scan to retrieve the dose-volume 
histogram, and on all diagnostic CT-scans at follow-up to 
calculate its volume (normal value 100-400 cc). Data on 
clinical adverse events, defined as pneumonia, fatal infection 
and thromboembolic event, were collected. Mixed effects 
and Cox regression models were used to evaluate radiation 
dose-dependent changes in spleen volume and clinical 
adverse events over time, considering age, comorbidity, 
chemotherapy, and surgery. 
Results: Forty-six out of 99 consecutive patients were 
evaluable. All patients received 45 Gy in 25 fractions 
(concurrent capecitabine n=8, capecitabine/cisplatin n=38). 
Neoadjuvant chemotherapy (epirubicine, cisplatin, 
capecitabine) was administered in 50%. Median follow-up 
time from the end of treatment until the last visit or death 
was 66 (95% CI 56-76) months. Median (range) V10, V20, V30, 
V40 and V45 of the spleen were 100 (84-100), 99.9 (78-100), 
91 (66-100), 60 (26-100) and 18 (3-93) % respectively, Dmean 
was 40 (32-46) Gy. Mean (95% CI) spleen volume decreased 
over time from 201 (173-234) cc to 82 (64-106) cc at 4 years 
(p<0.001), corresponding to a mean relative spleen volume of 
33 (29-38) % (figure). This was only associated with the V40 
(p=0.003), V45 (p<0.001) and Dmean (p=0.013). At follow-up, 
13 patients had 19 clinical adverse events (pneumonia n=13, 
fatal infection n=2, thromboembolic n=4). Mean onset time 
from the end of treatment to the first clinical event was 65 
(95% CI 54-76) months. The cumulative incidence increased in 
time. None of the tested factors were associated. 
